Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva

Currently, no effective therapies exist for fibrodysplasia ossificans progressiva (FOP), a rare congenital syndrome in which heterotopic bone is formed in soft tissues owing to dysregulated activity of the bone morphogenetic protein (BMP) receptor kinase ALK2 (also known as ACVR1). From a screen of...

Full description

Bibliographic Details
Main Authors: Eleanor Williams, Jana Bagarova, Georgina Kerr, Dong-Dong Xia, Elsie S. Place, Devaveena Dey, Yue Shen, Geoffrey A. Bocobo, Agustin H. Mohedas, Xiuli Huang, Philip E. Sanderson, Arthur Lee, Wei Zheng, Aris N. Economides, James C. Smith, Paul B. Yu, Alex N. Bullock
Format: Article
Language:English
Published: American Society for Clinical investigation 2021-04-01
Series:JCI Insight
Subjects:
Bone biology
Therapeutics
Online Access:https://doi.org/10.1172/jci.insight.95042

Internet

https://doi.org/10.1172/jci.insight.95042

Similar Items